EGFR protein expression detected by immunohistochemistry (IHC) is present in 60–90% of NSCLC patients [13], [38] and therefore unlikely to be of use for clinical selection for TKI therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.